LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025

Core Insights - LENZ Therapeutics is focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved eye drop for treating presbyopia in adults [1][3] - The company will host a webcast on November 5, 2025, to report its third quarter 2025 financial results and recent corporate highlights [1] Company Overview - LENZ Therapeutics is headquartered in San Diego, California, and is dedicated to providing access to VIZZ globally through licensing partnerships [3] - Presbyopia affects an estimated 1.8 billion people worldwide, including 128 million in the United States [3]